CLINICAL TRIALS PROFILE FOR HEPARIN LOCK FLUSH

All Clinical Trials for HEPARIN LOCK FLUSH

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	National Institute on Aging (NIA)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.

Clinical Trial Conditions for HEPARIN LOCK FLUSH

Condition Name

Condition Name for HEPARIN LOCK FLUSH
Intervention	Trials
Venous Thromboembolism	64
Pulmonary Embolism	45
Myocardial Infarction	30
Thrombosis	29

Condition MeSH

Condition MeSH for HEPARIN LOCK FLUSH
Intervention	Trials
Thrombosis	138
Thromboembolism	104
Venous Thrombosis	89
Venous Thromboembolism	76

Clinical Trial Locations for HEPARIN LOCK FLUSH

Trials by Country

Trials by Country for HEPARIN LOCK FLUSH
Location	Trials
United States	979
Canada	241
China	155
Germany	131
Italy	117

Trials by US State

Trials by US State for HEPARIN LOCK FLUSH
Location	Trials
Texas	77
New York	57
California	50
Ohio	44
Pennsylvania	41

Clinical Trial Progress for HEPARIN LOCK FLUSH

Clinical Trial Phase

Clinical Trial Phase for HEPARIN LOCK FLUSH
Clinical Trial Phase	Trials
Phase 4	271
Phase 3	216
Phase 2/Phase 3	46

Clinical Trial Status

Clinical Trial Status for HEPARIN LOCK FLUSH
Clinical Trial Phase	Trials
Completed	495
Recruiting	131
Unknown status	123

Clinical Trial Sponsors for HEPARIN LOCK FLUSH

Sponsor Name

Sponsor Name for HEPARIN LOCK FLUSH
Sponsor	Trials
M.D. Anderson Cancer Center	32
Sanofi	27
GlaxoSmithKline	20

Sponsor Type

Sponsor Type for HEPARIN LOCK FLUSH
Sponsor	Trials
Other	1362
Industry	334
NIH	58